Answers are grounded in this paper and cite their sources.
A 10-year-old, female shih tzu was diagnosed as having myelodysplastic syndrome (MDS) based on the presence of a nonregenerative anemia, dysplastic changes in the three hematopoietic cell lines, a normal to hypercellular bone marrow, and less than 30% blast cells of all nucleated cells in the bone marrow. Low-dose aclarubicin, a differentiation-induction therapy for MDS and atypical leukemias in humans, was administered. Hematological improvement was observed, and the dog lived for 809 days after the first presentation.
No takes yet. Share an insight, caveat, or question.
Miyamoto et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: